Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized booster study of intranasal LVT-001 versus Comirnaty JN.1 in healthy adults
2024-510589-17-00Phase 2Authorised
- Sponsor
- Inserm
- Start
- May 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing LVT-001 booster with Comirnaty JN.1 booster control (2 arms). Primary endpoints: Immediate adverse events after vaccination, Solicited local reactogenicity and 4 more. Planned start May 2025; status: authorised.
02
Drugs
LVT-001bretovameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-510589-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510589-17-00.